Anzeige
Mehr »
Donnerstag, 09.04.2026 - Börsentäglich über 12.000 News
Research Capital bestätigt $3,00 Kursziel - FUTR zündet die nächste Stufe: Vom Fintech zur globalen Finanzplattform
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41083 | ISIN: US68620A3023 | Ticker-Symbol: 4OR
Lang & Schwarz
09.04.26 | 07:00
1,220 Euro
-100,00 % -1,220
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
VIVOSIM LABS INC Chart 1 Jahr
5-Tage-Chart
VIVOSIM LABS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2101,23007:00

Aktuelle News zur VIVOSIM LABS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrVivoSim Labs, INC. - 8-K, Current Report4
01.04.VivoSim Labs prices $4 million public offering at $1.14/share4
01.04.VivoSim Labs prices $4M public offering at $1.14 per share5
01.04.VivoSim announces pricing of up to $4M public offering4
01.04.VivoSim Labs platziert Kapitalerhöhung über 4 Mio. US-Dollar zu 1,14 US-Dollar je Aktie5
01.04.VivoSim Labs, Inc.: VivoSim Announces Pricing of up to a $4 Million Public Offering5
VIVOSIM LABS Aktie jetzt für 0€ handeln
31.03.VivoSim Labs, INC. - S-1/A, General form for registration of securities2
30.03.VivoSim launches $4M offering with warrants and two-tranche structure5
27.03.VivoSim Labs, INC. - S-1, General form for registration of securities5
24.03.VivoSim validiert Leber- und Darmmodelle für ADC-Toxizitätstests20
24.03.VivoSim Labs, Inc.: VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs8
03.03.VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales306SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety...
► Artikel lesen
11.02.VivoSim Labs, INC. - 10-Q, Quarterly Report20
11.02.VivoSim Labs, Inc.: VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego28
30.01.Morning Market Movers: TechCreate, VivoSim Labs, La Rosa Holdings, Kaixin Holdings See Big Swings1.045BEIJING (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening...
► Artikel lesen
29.01.VivoSim Labs, Inc.: VivoSim Expands Asia-Pacific Access to NAMKind Human-Based Toxicology Services Through New Distributor Agreement in Korea and China30
06.01.VivoSim Labs, Inc.: VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer331SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing...
► Artikel lesen
18.12.25VivoSim Labs, INC. - 8-K, Current Report25
14.08.25VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer767SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing...
► Artikel lesen
24.04.25VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market810SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development....
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1